Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Marco Cerrano, Lazzarotto Davide, Eleonora Boscaro, Erika Borlenghi, Ilaria Tanasi, Patrizia Chiusolo, Paola Minetto, Francesco Grimaldi, Michelina Dargenio, Matteo Leoncin, Silvia Trappolini, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Patrizia Zappasodi, Roberta La Starza, Nicola Fracchiolla, Federica Di Biase, Maria Ilaria Del Principe, Marzia Defina, Crescenza Pasciolla, Benedetta Cambò, Federico Mosna, Daniela Pietrasanta, Sabrina Mariani, Valentina Mancini, Fabio Guolo, Federico Lussana, Elisabetta Todisco, Mario Annunziata, Valeria Calafiore, Maria Ciccone, Matteo Piccini, Matteo Emidio Dragani, Beatrice Sani, Endri Mauro, Claudia Basilico, Beatrice De Marco, Marco Antonacci, Laura Forlani, Monica Fumagalli, Fabio Trastulli, Monia Lunghi, Prassede Salutari, Sara Mastaglio, Sabina Chiaretti, Anna Candoni, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio

Blood (2024) 144 (Supplement 1): 113.

https://doi.org/10.1182/blood-2024-206854

Published: 2024

Journal Articles

CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study

Blood (2024) 144 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2024-210042

Published: 2024

Journal Articles

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Blood (2024) 144 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2024-205427

Published: 2024

Journal Articles

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Blood (2024) 144 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2024-198139

Published: 2024

Journal Articles

Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease

Carola Riva, Paola Minetto, Maria Chies, Elena Maio, Ylenia Azzanelli, Giada Zecchetti, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Giuseppina Fugazza, Paolo Nozza, Michele Cea, Roberto Massimo Lemoli, Fabio Guolo

Blood (2024) 144 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2024-198174

Published: 2024

Journal Articles

High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction

Fabio Guolo, Carola Riva, Maria Chies, Chiara Vernarecci, Ylenia Azzanelli, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Michele Cea, Roberto Massimo Lemoli, Paola Minetto

Blood (2024) 144 (Supplement 1): 1478.

https://doi.org/10.1182/blood-2024-198187

Published: 2024

Journal Articles

Excellent Outcome in NPM1- mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations

Paola Minetto, Carola Riva, Enrico Carminati, Ylenia Azzanelli, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Antonia Cagnetta, Michele Cea, Roberto Massimo Lemoli, Fabio Guolo

Blood (2024) 144 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2024-198171

Published: 2024

Journal Articles

Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification

Carola Riva, Paola Minetto, Maria Chies, Chiara Vernarecci, Giada Zecchetti, Elena Maio, Ylenia Azzanelli, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Paolo Nozza, Michele Cea, Roberto Massimo Lemoli, Fabio Guolo

Blood (2024) 144 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2024-197943

Published: 2024

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Blood (2023) 142 (Supplement 1): 731.

https://doi.org/10.1182/blood-2023-189025

Published: 2023

Journal Articles

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Chiara Vernarecci, Elena Maio, Mattia Montanari, Francesco Puglisi, Clara Nurra, Maurizio Miglino, Nicoletta Colombo, Enrico Carminati, Giada Zecchetti, Maria Chies, Beatrice Ferro, Massimo Zucchetti, Antonia Cagnetta, Michele Cea, Elisabetta Tedone, Roberto Massimo Lemoli, Fabio Guolo, Paola Minetto

Blood (2023) 142 (Supplement 1): 5879.

https://doi.org/10.1182/blood-2023-185082

Published: 2023

Journal Articles

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Blood (2023) 142 (Supplement 1): 5877.

https://doi.org/10.1182/blood-2023-182976

Published: 2023

Journal Articles

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Blood (2023) 142 (Supplement 1): 2918.

https://doi.org/10.1182/blood-2023-189417

Published: 2023

Journal Articles

Late Hematologic Recovery after CPX-351 Induction Chemotherapy in AML: Predictive Disease and Patient's Factors and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2023-182993

Published: 2023

Journal Articles

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Truly Refractory Hodgkin Lymphoma Patients Is Highly Effective and Responses Are Mediated By NK Cells

Blood (2023) 142 (Supplement 1): 2218.

https://doi.org/10.1182/blood-2023-189574

Published: 2023

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Discontinuation in Non-Allografted Ph+ Acute Lymphoblastic Leukemia Patients, a Campus ALL Real-Life Study

Matteo Dragani, Roberta Agrippino, Giovanna Rege Cambrin, Matteo Leoncin, Marco Cerrano, Prassede Salutari, Antonino Mulè, Cristina Papayannidis, Marzia Defina, Giulia Rivoli, Elisabetta Todisco, Elisabetta Abruzzese, Michele Cedrone, Nicola Fracchiolla, Fabio Guolo, Giuseppe Lanzarone, Robin Foà, Sabina Chiaretti

Blood (2023) 142 (Supplement 1): 2835.

https://doi.org/10.1182/blood-2023-187668

Published: 2023

Journal Articles

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

Blood (2023) 142 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2023-177951

Published: 2023

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

Carola Riva, Paola Minetto, Enrico Carminati, Maria Chies, Chiara Vernarecci, Beatrice Ferro, Elena Maio, Giada Zecchetti, Michela Frello, Maurizio Miglino, Elisabetta Tedone, Nicoletta Colombo, Clara Nurra, Francesco Puglisi, Antonia Cagnetta, Michele Cea, Giuseppina Fugazza, Roberto Massimo Lemoli, Fabio Guolo

Blood (2023) 142 (Supplement 1): 6016.

https://doi.org/10.1182/blood-2023-186555

Published: 2023

NARROW

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease

High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction

Excellent Outcome in NPM1- mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations

Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Late Hematologic Recovery after CPX-351 Induction Chemotherapy in AML: Predictive Disease and Patient's Factors and Their Impact on Survival

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Truly Refractory Hodgkin Lymphoma Patients Is Highly Effective and Responses Are Mediated By NK Cells

Tyrosine Kinase Inhibitor (TKI) Discontinuation in Non-Allografted Ph+ Acute Lymphoblastic Leukemia Patients, a Campus ALL Real-Life Study

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only